# Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children

> **NCT01982396** · PHASE1 · COMPLETED · sponsor: **PENTA Foundation** · enrollment: 19 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **DRUG:** ABC Twice Daily
- **DRUG:** ABC Once Daily
- **DRUG:** 3TC Once Daily
- **DRUG:** 3TC Twice Daily

## Key facts

- **NCT ID:** NCT01982396
- **Lead sponsor:** PENTA Foundation
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2004-02
- **Final completion:** 2004-03
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2013-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01982396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01982396, "Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01982396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*